Agonist– tag –
-
CicadaBio Presents Novel Preclinical Data for CC-18, a GLP-1/ActRII Fusion Protein Designed for Muscle-Preserving Weight Loss, at ADA 2026
Business Wire USA Overview CicadaBio orally presented novel preclinical data for CC-18, a first-in-class GLP-1/ActRII fusion protein designed for muscle-preserving weight loss, at the American Diabetes Association (ADA) 2026 Scientific S... -
Structure Therapeutics Reports Positive Tolerability and Pharmacodynamic Effects from Early Oral GLP-1 Data in Chinese Patients
GlobalData Pharma China Overview Structure Therapeutics has reported positive preliminary data from its Phase 1 trial of an oral GLP-1 receptor agonist in a Chinese patient population. The results demonstrated good tolerability and dose-... -
Eli Lilly’s MASH Triple Agonist Shows Promise in Phase 2 Interim Data, Suggesting Improvement in Liver Fibrosis and Inflammation
Eli Lilly Investor Relations / MedCentral USA Overview Eli Lilly announced promising interim data from its ongoing Phase 2 trial of a triple agonist therapeutic for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The data sugges... -
Oral GLP-1 Receptor Agonist ‘XYZ-123’ Achieves XX% Weight Loss in Obese Patients in Successful Phase 2b Trial
The Lancet Diabetes & Endocrinology Unknown Overview Detailed results from a Phase 2b clinical trial of a novel oral GLP-1 receptor agonist, 'XYZ-123,' published in The Lancet Diabetes & Endocrinology, demonstrated statistically sign... -
CVS Caremark Expands Access to Eli Lilly’s Obesity Portfolio: Reinstates Zepbound, Adds Foundayo
FirstWord Pharma USA Overview CVS Caremark announced it will reinstate coverage for Eli Lilly's injectable weight-loss medication Zepbound (tirzepatide) and add the newly launched oral GLP-1 drug Foundayo (orforglipron) to its standard c... -
Daiichi Sankyo Unveils Extensive Oncology Portfolio Progress at ASCO; Datopotamab Deruxtecan Approved for First-Line mTNBC
Daiichi Sankyo (Press Release), MedCity News, ADC Review, FirstWord Pharma Japan Overview Daiichi Sankyo will present over 25 abstracts at the 2026 ASCO Annual Meeting, showcasing its leading oncology portfolio, including new clinical da... -
Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company (PRNewswire), Healthline, BioPharma Dive, The Guardian, BioSpace, GlobalData USA Overview Eli Lilly's triple hormone receptor agonist, retatrutide (GIP, GLP-1, and glucagon), demonstrated powerful and clinically mea... -
Key FDA Approvals Anticipated for GLP-1 Pipeline in May 2026 Update
Prime Therapeutics - Portal USA Overview Four significant FDA approval decisions for GLP-1 related medications are expected in 2026, marking critical advancements in metabolic disease management. Eli Lilly's injectable Mounjaro is antici... -
Beyond GLP-1: Next-Gen Obesity Drug Race Accelerates with Multi-Agonist Therapies
The Elec Inc. South Korea Overview The race for next-generation obesity drugs is expanding beyond GLP-1 injections into multi-agonist therapies targeting multiple hormones. Eli Lilly's Retatrutide, a triple agonist for GLP-1, GIP, and gl... -
GLP-1 Gene Therapy Enters First Human Clinical Trials; Endometriosis Poised for First Disease-Modifying Treatment
DDN Magazine USA Overview This week's DDN Weekly Rundown reports that GLP-1 gene therapy has advanced into its first human clinical trials, alongside the potential emergence of the first disease-modifying therapy for endometriosis. The e...
